Aller au contenu principal
2025 review

Mucoepidermoid Carcinoma of the Breast: A Systematic Review of Clinicopathologic, Immunohistochemical, and Molecular Features

2Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : tr, it. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Mucoepidermoid carcinoma (MEC) of the breast is a very rare salivary gland-like tumor, accounting for 0.2%-0.3% of all breast cancers (BC). This study aims to review the literature on MEC of the breast. METHODS: This systematic review focuses on MEC of the breast, conducted in line with PRISMA 2020 guidelines and registered in PROSPERO under ID CRD420251089598. Searches were performed in PubMed, Medline, Scopus, Web of Science, and Google Scholar, using terms such as "mucoepidermoid carcinoma," "breast," and similar terms. No language restrictions were applied. Studies published between January 1, 1979, and July 1, 2025, were included. RESULTS: Median age was 57 years (95% CI: 53-60). The most common presentation was a palpable breast mass (64.7%), followed by incidental detection via mammography (10.6%). Tumors were located in the left breast (49.4%) and in the right breast (43.5%). The most frequent tumor localization was the upper-outer quadrant (20.0%). Median tumor size was 21 mm (95% CI: 19-30). Modified radical mastectomy (30.6%) was the most common surgical approach, followed by breast-conserving surgery with sentinel or level dissection (29.4%), and simple mastectomy or its variants (17.6%). Immunohistochemistry revealed positivity for P63 (52.9%), CK5/6 (41.2%), CK7 (45.9%), Ki67 (44.7%), ER (24.7%), PR (4.7%), and HER2 (9.4%) with TNBC phenotype (36.5%), genetic alterations (16.5%), and distant metastasis (9.4%). Follow-up data revealed 7 deaths, of which 5 were due to MEC, and these five patients consistently exhibited poor prognostic features. Compared to the 63 survivors with follow-up data, they showed significantly higher rates of axillary lymph node positivity (p = 0.005) and advanced N stage (p = 0.001); in addition, all five had high-grade tumors (p = 0.001) and documented distant metastases (p < 0.001). CONCLUSION: Breast MEC is a rare malignancy with generally favorable prognosis in low-grade cases, but high-grade tumors show more aggressive behavior. In this study, all disease-related deaths occurred in high-grade tumors with axillary node involvement, advanced N stage, and distant metastasis-highlighting their prognostic significance. CK5/6, CK7, and P63 were frequently positive, whereas hormone receptors were usually negative. Close follow-up is essential, especially for high-grade tumors. REVIEW REGISTRATION: This systematic review was prospectively registered in the PROSPERO database under the registration number CRD420251089598.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Mucoepidermoid Carcinoma of the Breast: A Systematic Review of Clinicopathologic, Immunohistochemical, and Molecular Features
Date Crossref
01/09/2025
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Salivary Gland Tumors Diagnosis and TreatmentBreast Lesions and CarcinomasOcular Oncology and Treatments

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.